CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell heard the latest at the American Society of Clinical Oncology’s 2013 meeting in Chicago from Dr. Mario Sznol MD, Clinical Research Program Leader at Yale Cancer Center, New Haven, CT and Dr. Lynn Schuchter Chief of Hematolgy/Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
You may also like...
Breast Cancer Prognostic Implications of Obesity and Insulin Resistance 28 Mar, 2015 Virus Plus Cytokine Fight Primary and Metastatic Cancer 15 Aug, 2007 Geriatric Assessment Improved Outcomes for Older Patients with Cancer 11 Jul, 2018 Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos 5 Aug, 2009
- Previous story Combination immunotherapy improved overall survival in patients with metastatic melanoma
- Next story Novel oral anticoagulants: latest opinion from the ESC congress
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014